295P Clinical characterization and outcome of a HER2-low metastatic breast cancer (mBC) cohort receiving first-line treatment (1L) with ET +/- CDK 4/6 inhibitor (CDKi)

Authors :: D. Zara
Debora Basile
Lorenzo Gerratana
C. Noto
G. Targato
L. Palmero
Alessandro Marco Minisini
Claudia Andreetta
M. Alberti
F. Puglisi
Gaetano Pascoletti
E. Poletto
Gianpiero Fasola
S. Buriolla
Mauro Mansutti
Stefania Russo
L. Bortot
Marta Bonotto
Source :: Annals of Oncology. 32:S493
Publication Year :: 2021
Publisher :: Elsevier BV, 2021.

Subjects :: Oncology
medicine.medical_specialty
biology
business.industry
Hematology
medicine.disease
Metastatic breast cancer
First line treatment
Cyclin-dependent kinase
Internal medicine
Cohort
medicine
biology.protein
business

Full Text Access

Tools